IBRX · ImmunityBio, Inc.
$8.07
+0.58 (+7.67%)
At close · Jul 21
Going-concern doubt
— cleared May 7, 2026
The latest filing states the doubt was alleviated.
“As a result of continuing anticipated operating cash outflows as we commercialize our approved product and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash and cash equivalents, and investments in marketable securities; sales of our approved product; capital to be raised through equity offerings; and our potential ability to borrow from affiliated entities will be sufficient to fund our operations through at least the next 12 months following the issuance date of the condensed consolidated financial statements, including our Founder, Executive Chairman and Global Chief Scientific and Medical Officer's intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt.”View the 10-Q filed May 7, 2026
Market Cap
$8.45B
Shares
1.05B
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-06-30 | 532,679 | $8.77 | $4,671,595 |
| 2026-06-29 | 524,265 | $8.71 | $4,566,348 |
| 2026-06-26 | 30,732 | $7.79 | $239,402 |
| 2026-06-25 | 381,725 | $7.80 | $2,977,455 |
| 2026-06-24 | 183,840 | $7.32 | $1,345,709 |
| 2026-06-23 | 287,922 | $7.22 | $2,078,797 |
| 2026-06-22 | 333,592 | $7.36 | $2,455,237 |
| 2026-06-18 | 92,190 | $6.99 | $644,408 |
| 2026-06-17 | 836,971 | $6.72 | $5,624,445 |
| 2026-06-16 | 25,718 | $7.13 | $183,369 |
| 2026-06-15 | 234,660 | $7.10 | $1,666,086 |
| 2026-06-12 | 168,753 | $7.20 | $1,215,022 |
| 2026-06-11 | 567,162 | $6.98 | $3,958,791 |
| 2026-06-10 | 280,018 | $7.25 | $2,030,131 |
| 2026-06-09 | 105,934 | $7.17 | $759,547 |
| 2026-06-08 | 454,143 | $6.92 | $3,142,670 |
| 2026-06-05 | 156,280 | $7.29 | $1,139,281 |
| 2026-06-04 | 20,532 | $7.18 | $147,420 |
| 2026-06-03 | 253,044 | $7.23 | $1,829,508 |
| 2026-06-02 | 648,784 | $7.24 | $4,697,196 |
| 2026-06-01 | 351,007 | $7.52 | $2,639,573 |
| 2026-05-29 | 142,175 | $7.72 | $1,097,591 |
| 2026-05-28 | 865 | $7.89 | $6,825 |
| 2026-05-27 | 561,378 | $7.92 | $4,446,114 |
| 2026-05-26 | 145,546 | $7.22 | $1,050,842 |
| 2026-05-22 | 209 | $7.74 | $1,618 |
| 2026-05-21 | 27,265 | $8.05 | $219,483 |
| 2026-05-20 | 44,759 | $7.76 | $347,330 |
| 2026-05-18 | 28,100 | $7.97 | $223,957 |
| 2026-05-15 | 4,113 | $8.15 | $33,521 |
| 2026-05-14 | 3,455 | $8.15 | $28,158 |
| 2026-05-13 | 6,764 | $8.12 | $54,924 |
| 2026-05-12 | 32,535 | $8.11 | $263,859 |
| 2026-05-11 | 40,703 | $8.51 | $346,383 |
| 2026-05-08 | 87,758 | $7.76 | $681,002 |
| 2026-05-07 | 84,258 | $8.38 | $706,082 |
| 2026-05-06 | 175,248 | $7.58 | $1,328,380 |
| 2026-05-05 | 3,432 | $7.43 | $25,500 |
| 2026-05-04 | 186,036 | $7.11 | $1,322,716 |
| 2026-05-01 | 81,295 | $7.10 | $577,195 |
| 2026-04-30 | 828 | $6.96 | $5,763 |
| 2026-04-29 | 112 | $6.96 | $780 |
| 2026-04-28 | 115,803 | $7.29 | $844,204 |
| 2026-04-27 | 65,032 | $7.44 | $483,838 |
| 2026-04-24 | 21,997 | $8.19 | $180,155 |
| 2026-04-23 | 21,256 | $8.07 | $171,536 |
| 2026-04-22 | 48,059 | $8.10 | $389,278 |
Showing 1–47 of 47 settlements
Key facts
CIK
1326110
CUSIP
45256X103
13F (30d)
64 filings
64 filers
Visit website
Investor relations